SCHEMBL801352

SCHEMBL801352

CC(C)(C)CC(N)C(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2627108 1.00 DPP4 (0.33) DPP4
SCHEMBL24994972 1.00 DPP4 (0.33) DPP4
SCHEMBL23139737 0.78
SCHEMBL14560944 0.77
SCHEMBL15425574 0.75
SCHEMBL2627099 0.75 FDPS (0.31)
SCHEMBL18197848 0.75 FDPS (0.31)
SCHEMBL18880028 0.75 DPP4 (0.31) DPP4
SCHEMBL12961609 0.73 DPP4 (0.30) DPP4
SCHEMBL14050397 0.73 TSHR (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016940-A1 LONG-ACTING AND LONG-CIRCULATING DELIVERY VEHICLES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-01-18 US disclosed
EP-3950918-A1 CELL CULTURE SCAFFOLD MATERIAL, CELL CULTURE VESSEL, CELL CULTURE FIBER AND METHOD FOR CULTURING CELL SEKISUI CHEMICAL CO., LTD. (JP) 2022-02-09 EP disclosed
US-11071693-B2 Direct dental filling composition DENTSPLY SIRONA INC. (US) 2021-07-27 US disclosed
WO-2021055759-A1 SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USE GLYSCEND, INC. (US) 2021-03-25 WO disclosed
WO-2021055752-A1 BENZOXABOROLE POLYMERS AND METHODS OF USE GLYSCEND, INC. (US) 2021-03-25 WO disclosed
US-20210063888-A1 METHOD FOR FORMING PATTERNED PHOTORESIST TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) 2021-03-04 US disclosed
EP-3235836-B1 POLYMER SUMITOMO CHEMICAL CO (JP) 2020-10-21 EP disclosed
WO-2020203769-A1 CELL CULTURE SCAFFOLD MATERIAL, CELL CULTURE VESSEL, CELL CULTURE FIBER AND METHOD FOR CULTURING CELL 積水化学工業株式会社 2020-10-08 WO disclosed
WO-2020203770-A1 CELL CULTURE SCAFFOLD MATERIAL, CELL CULTURE VESSEL, CELL CULTURE CARRIER, CELL CULTURE FIBER AND CELL CULTURE METHOD 積水化学工業株式会社 2020-10-08 WO disclosed
US-10781218-B2 Substituted inhibitors of menin-MLL and methods of use KURA ONCOLOGY, INC. (US) 2020-09-22 US disclosed
US-20120067209-A1 GAS SEPARATION MEMBRANE NTNU TECHNOLOGY TRANSFER AS (NO) 2012-03-22 US disclosed
US-20110287262-A1 NANOPARTICLES, NANOCAPSULES AND NANOGELS UNIVERSITY OF KANSAS 2011-11-24 US disclosed
US-20110100830-A1 CHEMICAL CONVERSION TREATMENT SOLUTION FOR A STEEL MATERIAL AND CHEMICAL CONVERSION TREATMENT METHOD HENKEL AG & CO., KGAA (DE) 2011-05-05 US disclosed
US-20100316589-A1 Coated Pharmaceutical Compositions GENZYME CORPORATION 2010-12-16 US disclosed
US-20090226392-A1 Phosphate-Binding Polymers for Oral Administration GELTEX, INC. 2009-09-10 US disclosed
EP-1765907-B1 CURABLE COMPOSITIONS WITH AN IMPROVED ADHESION PERFORMANCE HENKEL AG & CO KGAA (DE) 2009-08-26 EP disclosed
EP-2067882-A1 METHOD OF TREATING SURFACE OF METAL BASE, METALLIC MATERIAL TREATED BY THE SURFACE TREATMENT METHOD, AND METHOD OF COATING THE METALLIC MATERIAL Nippon Paint Co., Ltd. (JP) 2009-06-10 EP disclosed
US-7459151-B2 Phosphate-binding polymers for oral administration GENZYME CORPORATION (US) 2008-12-02 US disclosed
US-20080179188-A1 METHODS, COMPOSITIONS AND DEVICES, INCLUDING ELECTROOSMOTIC PUMPS, COMPRISING COATED POROUS SURFACES EKSIGENT TECHNOLOGIES, INC. (US) 2008-07-31 US disclosed
EP-1923363-A2 Hydrophilic member and substrate for hydrophilic member FUJIFILM Corporation (JP) 2008-05-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090226392-A1 Phosphate-Binding Polymers for Oral Administration PHPT1, SLC34A2, ALPI DPP4 685/4885
US-20240016940-A1 LONG-ACTING AND LONG-CIRCULATING DELIVERY VEHICLES VEGFA, LDLR, LIPG DPP4 3384/4885
US-20110287262-A1 NANOPARTICLES, NANOCAPSULES AND NANOGELS KCNA6, CD44, KCNA5 DPP4 3111/4885
US-20100316589-A1 Coated Pharmaceutical Compositions SLC20A2, PHOSPHO1, SLC20A1 DPP4 2020/4885
US-10781218-B2 Substituted inhibitors of menin-MLL and methods of use MLLT1, MEN1, MLLT3 DPP4 3904/4885
US-11071693-B2 Direct dental filling composition CAD, DOCK5, ITGA5 DPP4 3913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.